Premium
Serum Bactericidal Activity of Extended‐Release Clarithromycin Against Macrolide‐Resistant Strains of Streptococcus pneumoniae
Author(s) -
Stein Gary E.,
Schooley Sharon
Publication year - 2002
Publication title -
pharmacotherapy: the journal of human pharmacology and drug therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.227
H-Index - 109
eISSN - 1875-9114
pISSN - 0277-0008
DOI - 10.1592/phco.22.8.593.33214
Subject(s) - clarithromycin , streptococcus pneumoniae , microbiology and biotechnology , streptococcaceae , antibacterial agent , titer , minimum inhibitory concentration , antibiotics , medicine , pneumococcal infections , pharmacokinetics , pharmacology , biology , virology , virus
Study Objective. To investigate the serum bactericidal activity (SBA) over time of extended‐release clarithromycin against moderately resistant strains of Streptococcus pneumoniae . Design. Prospective, single‐dose pharmacodynamic study. Setting. University‐affiliated research center. Subjects. Eleven healthy male volunteers. Intervention. All volunteers received a single dose of extended‐release clarithromycin as two 500‐mg tablets, and blood samples were obtained at 0, 2, 6, 12, and 24 hours after administration of the dose. Measurements and Main Results. For each blood sample, a serum bactericidal titer (SBT) was determined against S. pneumoniae strains with minimum inhibitory concentrations (MICs) of 0.5, 1.0, 2.0, 4.0, and 8.0 μg/ml to clarithromycin. The median SBT was determined for each time period. The extended‐release formulation of clarithromycin exhibited SBA for 24 hours against pneumococcal strains with MICs of 0.5, 1.0, and 2.0 μg/ml. No SBA was observed against isolates with MICs of 4.0 or 8.0 μg/ml. Conclusion. The extended‐release formulation of clarithromycin, taken once/day, will provide SBA for 24 hours against strains of S. pneumoniae with MICs of 2.0 μg/ml or less.